Can China’s home-grown mRNA Covid-19 vaccine pass its final tests?

China has moved a step closer to developing a home-grown mRNA vaccine against Covid-19, with the publication of early trial results for its prime candidate ARCoV.No serious adverse events were recorded in the phase 1 clinical trial data, published last week by The Lancet Microbe, but scientists said it was too early to judge its success.Large-scale trials of the vaccine – jointly developed by the Academy of Military Science, Walvax Biotechnology and Suzhou Abogen Biosciences – have been delayed…South China Morning Post